NCT01318889

Brief Summary

Oral mucositis can be a significant problem for cancer patients. It is typically associated with pain and increased risk of infection and can lead to impaired nutritional status and inadequate hydration.it can be seen in the patient population receiving high-dose head and neck radiation therapy (85%-100%). Topical dexpanthenol acts like a moisturizer, improving stratum corneum hydration, reducing transepidermal water loss and maintaining skin softness and elasticity. The stimulation of epithelization, granulation and mitigation of itching were the most prominent effects of formulations containing dexpanthenol. The investigators suppose that dexpanthenol mouth wash may improve oral mucositis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Sep 2010

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2010

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 8, 2011

Completed
13 days until next milestone

First Posted

Study publicly available on registry

March 21, 2011

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2011

Completed
Last Updated

July 6, 2011

Status Verified

June 1, 2010

Enrollment Period

1 year

First QC Date

March 8, 2011

Last Update Submit

July 5, 2011

Conditions

Keywords

DexpanthenolRadiotherapychemotherapyMucositis

Outcome Measures

Primary Outcomes (1)

  • reduction of intensity of mucositis

    measuring of the intensity of mucositis by visual examination and asking the patient about pain and discomfort

    first week (week one)

Study Arms (1)

normal saline

EXPERIMENTAL

mouth wash of normal saline ,three times a day, 10 cc each time

Drug: Dexpanthenol

Interventions

5% dexpanthenol Mouth wash , three times a day, 10 cc each time

Also known as: Physiologic serum
normal saline

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • without any systemic disease
  • estimated survival of at least 6 months
  • without any mental disorders
  • grade 1 to 3 WHO mucositis

You may not qualify if:

  • development of grade 4 WHO mucositis
  • Brachytherapy
  • allergy to the drug
  • dissatisfaction of the patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ShaheedBeheshti medical university

Tehran, Iran

RECRUITING

MeSH Terms

Conditions

StomatitisUlcerMucositis

Interventions

dexpanthenol

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsGastroenteritisGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • Fahimeh Anbari, resident

    dental faculty of shaheed Beheshti medical university

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fahimeh Anbari, resident

CONTACT

Jamileh beigom Taheri, professor

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 8, 2011

First Posted

March 21, 2011

Study Start

September 1, 2010

Primary Completion

September 1, 2011

Study Completion

September 1, 2011

Last Updated

July 6, 2011

Record last verified: 2010-06

Locations